{"id":"W1521559493","doi":"10.1002/cncr.29227","title":"A phase II trial of second‐line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma","year":2015,"lang":"en","type":"article","venue":"Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network; University of Calgary; Princess Margaret Cancer Centre","funders":"","keywords":"Axitinib; Medicine; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Progressive disease; Hepatocellular carcinoma; Internal medicine; Adverse effect; Gastroenterology; Oncology; Sorafenib; Urology; Clinical trial; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001598744,0.001151224,0.001461312,0.0003979396,0.0003464696,0.0007014388,0.000549651,0.0009621525,0.004947936],"category_scores_gemma":[0.0007488374,0.0004087248,0.0009313457,0.0003105389,0.0006718593,0.0005572721,0.0003066436,0.00280615,0.001116037],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007818114,"about_ca_system_score_gemma":0.00169402,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008316963,"about_ca_topic_score_gemma":0.002112473,"domain_scores_codex":[0.9996669,0.0001436904,0.00001793747,0.00005254857,0.00004022412,0.00007853077],"domain_scores_gemma":[0.9993467,0.00008298933,0.00009593955,0.00006660867,0.00004503479,0.000362731],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.77746,0.06672584,0.006960975,0.0009466225,0.001203516,0.0004360026,0.0002440419,0.00211754,0.03627216,0.0003367095,0.007158666,0.1001379],"study_design_scores_gemma":[0.736578,0.2497346,0.006073656,0.00002633053,0.0002147258,0.0003180937,0.00002843745,0.001199124,0.003302279,0.0001105439,0.002395651,0.00001868412],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9904265,0.00170179,0.0006478587,0.0006796582,0.0002510736,0.002944459,0.0009276945,0.0001148113,0.002306266],"genre_scores_gemma":[0.9851192,0.001452672,0.001386468,0.0008968575,0.0002276524,0.003832253,0.002896148,0.00002772472,0.004160976],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004947936,"threshold_uncertainty_score":0.01655245,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1064780361000544,"score_gpt":0.3306505208578445,"score_spread":0.2241724847577901,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}